ISPOR - PMH28 Using Cost-Effectiveness Analysis to Define the Optimal Group of Patients to Benefit From Risperidone Long-Acting Injectable

Full Text

PMH28 Using Cost-Effectiveness Analysis to Define the Optimal Group of Patients to Benefit From Risperidone Long-Acting Injectable

Abstract

Authors

A. Valencia-Mendoza A. Hernández-Garduño

Back to Volume 15, Issue 7

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now